Moderna's AI-developed skin cancer vaccine passes phase 3 trials

According to media reports, artificial intelligence played a key role in developing the drug. The vaccine is administered after tumor removal and blocks the recurrence of cancer cells. Following the news, Moderna's shares surged nearly 180% over 24 hours.